Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6738010 | 0.77 | — | — | |
| SCHEMBL6740230 | 0.76 | — | — | |
| SCHEMBL7854176 | 0.68 | CRHR1 (0.30) | — | |
| SCHEMBL6738349 | 0.66 | — | — | |
| SCHEMBL7078722 | 0.66 | NPY1R (0.38) | — | |
| SCHEMBL7843463 | 0.65 | GRM8 (0.32) | — | |
| SCHEMBL6814847 | 0.61 | — | — | |
| SCHEMBL16882591 | 0.59 | SLC6A2 (0.41) | — | |
| SCHEMBL3206456 | 0.59 | ADORA1 (0.35) | — | |
| SCHEMBL6822467 | 0.58 | KMT5A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055059-A1 | For therapy of psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease | GILLIGAN PAUL JOSEPH (US) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055059-A1 | For therapy of psychiatric disorders and neurological diseases including affective disorder, anxiety, depression, headache, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease | CRH, PCNP, CRHR1 | CREBBP 1107/4885CACNA1H 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.